TWIST Talk by Curt Bilby
Technology Commercialization: An unconventional path for unconventional people
Abstract
Technology commercialization has been with us for decades. While the processes, protocols and models are becoming more refined and better understood, the path is still full of challenges, failures and rewards. Successful technology commercialization often requires a unique mindset and approach, calling us to bridge the gap between universities, businesses, investors, and governments, but we do not always speak the same language.
Let us share and discuss some behind-the-scene examples that might allow us to reset some of our expectations.
Biography
Curt Bilby has over twenty-five years of executive leadership experience in both the US and Europe focused on technology commercialization, company growth and shareholder value across several markets and technologies.
Dr. Bilby is currently the President and CEO of Art Analysis & Research - the leading provider of scientific testing of artworks to support authentication. Previous to his venture in the art market, he was the President and CEO of Terapio Corporation, a biopharmaceutical company developing a countermeasure for radiation and chemical poisoning in mass casualty situations based on university technology. Prior to that, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation, which commercialized a biosensor for pathogen detection based on technology developed at the Naval Research Laboratory. He was the Chairman and CEO of Evacyte Corporation, a company that commercialized a laser-based cancer detection and cell diagnostic founded on university technology. Dr. Bilby also served as the Président-Directeur Général of Eurimed, S.A. headquartered in Paris, France.
Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin. Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.
In order for us to track the registrations, please register here.
You can directly join the webinar without registration via the links below: